ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO525

Effectiveness of Inactivated Hantavirus Vaccine on the Disease Severity of Hemorrhagic Fever with Renal Syndrome

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Yi, Yongjin, Armed Forces Capital Hospital, Seongnam-si, GYEONGGI-DO, Korea (the Republic of)
  • Park, Hayne C., Kangnam Sacred Heart Hospital, Seoul, Korea (the Republic of)
Background

An inactive Hantaan virus vaccine (iHV) has been broadly used as a preventive strategy in the South Korean army. After the vaccination program, the overall incidence of Hantavirus cases was reduced. However, hundreds of new HFRS cases occur annually. Furthermore, few studies have demonstrated the efficacy of the iHV’s in field settings. This study aimed to evaluate the vaccine efficacy on HFRS severity.

Methods

From 2009 to 2017, we registered all reported Hantavirus cases in the South Korean army hospitals along with the patients’ vaccination history. We retrospectively classified HFRS patients into both groups according to their vaccination records: no history of iHV vaccination and valid vaccination. To evaluate the vaccine efficacy on the severity of renal injury, acute kidney injury (AKI) ≧ stage 3 and event of dialysis were investigated.

Results

We assessed the effect of the vaccine on severity in 18 and 110 HFRS patients with and without valid vaccination history, respectively. In the valid-vaccination group, six of 18 patients (33.3%) had stage 3 AKI, compared to 60 of 110 (54.5%) HFRS patients in the non-vaccination group. The vaccine efficacy against HFRS progression (VEp) was 58.1% (95% confidence interval [CI]: -31.3–88.0%).

Conclusion

The vaccine efficacy against the progression of HFRS in this case-control study failed to show a statistically significant result. However, different severity profiles were observed between the vaccinated and none-vaccinated groups. More studies with large vaccinated populations are needed to demonstrate the effectiveness of the vaccine in patients with HFRS.

Funding

  • Government Support - Non-U.S.